Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases
Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).
In the fact box to the right there is a link to the Reimbursement Committee's recommendation in which there is a list with links to the references on which the Committee has based its recommendation.
The Danish Medicines Agency has initiated the hearing of companies holding marketing authorisations for medicinal products comprised by the Reimbursement Committee's recommendation. A copy of the Danish Medicines Agency's letter is in the fact box.
The deadline for submitting comments is Monday, 5 May 2008.
A notification about the Reimbursement Committee's recommendation has also been sent to the relevant Danish scientific societies, the National Board of Health and the Institute for Rational Pharmacotherapy.
For further information, please contact the Reimbursement Department, Send an email.
The Danish Medicines Agency, 14 February 2008